Bristol Myers pays $80M to license another Prothena neuroscience candidate

Bristol Myers Squibb is shelling out $80 million to Prothena for an exclusive global license for an early-stage neurodegenerative candidate, as the pharma giant continues …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

NCCN 2024 Annual Conference focuses on practical applications for improving cancer care

The National Comprehensive Cancer Network (NCCN)-;an alliance of leading cancer centers-;hosted more than 1,700 oncology professionals during the NCCN 2024 Annual Conference on April 5-7.

April 13, 2024

Essence SmartCare, Skyresponse Partner to Expand Ageing-In-Place Products Across Europe

What You Should Know: Essence SmartCare, part of Essence Group, a global leader in IoT remote care solutions, today announced the integration of Care@Home, an

September 10, 2024

TRIPP Takes VR Meditation to New Heights on Apple Vision Pro

What You Should Know: – TRIPP, the award-winning wellness company, announces its arrival on the highly anticipated Apple Vision Pro, redefining the boundaries of personalized

February 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.